Discover Evalution®

With Evalution® you find  more
clinical information faster

Join our partners

  • Drug development solutions

    For pharma customers we co-develop your companion Diagnostic Assay

  • Service Lab partnering

    To provide your customers with novel solutions in Assay development

  • Integrated solutions

    Integrate our DMAT® technology as reader inside your own IVD platform

  • Porting novel biomarkers on the platform

    We partner with biomarker discovery companies and port their panels on our Evalution® platform

Partner quotes

"The unique combination of multiplexing, sensitivity and flexibility turns the Evalution platform into an indispensable tool for the life science R&D market"

Dr.Ir. Karen Leirs
Postdoctoral Researcher
KU Leuven Biosensors group

"Thanks to the characteristics of the microflow, creations of novel or specialized immunoassays are just as easy as running conventional ones. Together with the flexibility of the particles, Evalution offers a solution not met elsewhere."

Maja Neiman, Ph.D.
Head of Autoimmunity Profiling Facility
Affinity Proteomics, SciLifeLab, Stockholm
KTH - Royal Institute of Technology

Clinical domains which are relevant for MyCartis’ technology

Significant progress in assay development

Mycartis has published a Whitepaper entitled “Making more organs available for successful transplantation”.

MyCartis has made significant progress in the development of a fast (<30min) immunoassay to objectively assess the fitness of a donor organ during perfusion as well as predict the post-surgery acceptance and survival. This is the first time that an assay meets the required analytical performance criteria required in this emerging field and is ideally suited for repeat (interval) testing during the organ perfusion process. These assay characteristics are made possible through a combination of DMAT® features as well as unique Evalution® platform concepts. When implemented, the transplant surgeon would get timely insight on the organ fitness and gain confidence in the successful outcome of this life-saving procedure.

MyCartis has engaged with a specialized transplant centre to run its first pre-clinical tests in a clinical environment. As a first model case, donor lung organs undergoing perfusion are objectively assessed for their inflammation status using an ultra-fast and reliable IL-1β assay, a choice based on the findings of Prof. Dr. Andrew Fisher (Newcastle) who demonstrated that this biomarker can be predictive on organ fitness as well as subsequent acceptor survival. Together with its fast turnaround time, Evalution®’s specific cartridge form factor allows for repeat testing of the organ, allowing the transplant surgeon to decide on the right timing for transplantation. The same unique model assay concept can be easily applied to other biomarkers, enabling multiplex organ perfusion panel testing. Such perfusion procedure and companion test has the potential of making available for transplant 30% more organs from the initially rejected ones and could therefore have a serious positive effect on waiting list size and mortality. The market potential of perfusion is growing at a double digit CAGR and expands from lungs into heart, liver and other solid organs.

Download the White Paper.

DMAT® Technology

Dynamic Multi-Analyte Technology (DMAT®) offers simultaneous end-point and real-time measurement of multiple biomarkers with minimum assay variability. It supports a variety of assay formats, such as sandwich assays for measuring biomarkers and (in)direct assays for quantifying specific antibodies in samples.

Evalution® is an integrated system based on three elements: the instrument, the disposable: cartridge with micro-particles inside and the software containing advanced analysis algorithms. No additional equipment is required.

Download PDF for more information


Cartridge with encoded microparticles

Software and data analysis algorithms

Evalution® Platform Configurations

MyCartis’ proprietary platform Evalution® is powered by DMAT®. It brings all the DMAT® benefits and features, such as ultra-fast real-time assays and minimal assay variability. Evalution® comes in 3 different configurations, each designed to provide a unique solution to life science R&D, clinical research and routine clinical diagnostics respectively.

Evalution® Research & Development

Evalution® Automation

Evalution® Clinical Diagnostics